Capricor Therapeutics, Inc., a clinical-stage biotechnology company, has recently garnered attention due to a significant equity transaction. On January 31, 2026, Tang Capital Management LLC acquired a substantial stake in the company, marking a notable development in its financial landscape. This move has placed Capricor Therapeutics in the spotlight, as no further disclosures have been made since the transaction.
Operating within the healthcare sector, Capricor Therapeutics is dedicated to the development and commercialization of biological therapies aimed at treating Duchenne muscular dystrophy (DMD) and other rare disorders. Based in Beverly Hills, United States, the company serves markets in both the US and Canada. For those interested in learning more about their innovative work, additional information is available on their website at www.capricor.com . The company is publicly traded on the Nasdaq stock exchange under the ticker symbol CPRC.
Recent market data reveals that Capricor Therapeutics’ stock closed at $21.89 on the most recent trading day. Over the past year, the stock has experienced significant volatility, with a 52-week high of $40.37 on December 2, 2025, and a low of $4.30 on November 24, 2025. This wide price swing underscores the stock’s volatility and the dynamic nature of its market performance.
Financially, Capricor Therapeutics presents a unique profile. The price-to-earnings ratio stands at -12.17, indicating negative earnings per share. This suggests that the company is not currently profitable, a common scenario for many biotechnology firms in the clinical stage of development. Additionally, the price-to-book ratio is 12.32, highlighting that investors are valuing the company based on its balance-sheet assets rather than its earnings performance.
With a market capitalization of approximately $1.19 billion, Capricor Therapeutics’ valuation metrics emphasize its book value over profitability. This focus on balance-sheet assets rather than earnings is indicative of investor confidence in the company’s potential future growth and its strategic assets.
In summary, Capricor Therapeutics, Inc. is a company characterized by active ownership interest, substantial price volatility, and valuation metrics that prioritize book value. As it continues to advance its clinical-stage therapies, the company remains a focal point for investors and stakeholders within the biotechnology and healthcare sectors.
